About Slow-Channel Congenital Myasthenic Syndrome
Slow-Channel Congenital Myasthenic Syndrome is caused by dominant gain-of-function mutations in genes encoding nicotinic acetylcholine receptor (AChR) subunits, prolonging channel open time and causing calcium-mediated excitotoxic damage to the end-plate and subsynaptic myonuclei. It is distinguished from other CMS subtypes by its dominant inheritance, characteristic end-plate myopathy on biopsy, and selective weakness of cervical, scapular, and finger extensor muscles. It is specifically treated with quinidine or fluoxetine, which shorten channel open time.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Slow-Channel Congenital Myasthenic Syndrome trials.
Genetic confirmation of a dominant pathogenic AChR subunit mutation is required; AChR antibodies are negative in CMS (differentiating it from myasthenia gravis) — confirm seronegative status in your records
Repetitive nerve stimulation (RNS) showing repetitive CMAP and single-fibre EMG showing increased jitter are key diagnostic electrophysiological findings required for most trials
Current medications including quinidine or fluoxetine may necessitate washout periods; discuss medication management with your neurologist well before a planned trial application
Patient Resources
Find recruiting Slow-Channel Congenital Myasthenic Syndrome trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Slow-Channel Congenital Myasthenic Syndrome. Updated daily.